Biomarker Deals: Terms, Value and Trends, 2008-2018
Report Scope:
This report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this study covers the U. S. and companies worldwide. The report identifies the main elements in licensing, acquisitions and partnership deals in the biomarker industry.
Report Includes:
This report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this study covers the U. S. and companies worldwide. The report identifies the main elements in licensing, acquisitions and partnership deals in the biomarker industry.
Report Includes:
- 43 data tables and 42 additional tables
- An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including detailed analysis of deals structure and their potential values
- Information about significant players in this field of study, trends and obstacles, and other information affecting biomarker market development
- Review of business terms and conditions of deals in the biomarker market, with focus on major trends in biomarker deal making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
- Essential information to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
- Identification of the main elements in licensing, acquisitions and partnership deals in the biomarker industry
- Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis et al.
- Details of various types of biomarkers deals and milestone payments and their value in different deals
- Examination of competitive landscape and detailed profiles of major companies developing biomarkers, including bioMerieux SA, IntegraGen SA, MDxHealth, Myriad Genetics, Protagen AG and Qiagen
CHAPTER 1 INTRODUCTION=
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources and Methodology
Intended Audience
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS=
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND=
Biomarker Definition and Classification
Biomarker Applications
Biomarker Identification and Detection Technologies
Steps in Biomarker Development
Biomarker Market Analysis and Evaluation
Global Biomarker Market Value and its Segmentation
Oncology-Related Biomarkers Sector
Cardiovascular Diseases Biomarker Sector
Neurological Disorders and Other Diseases Biomarkers Sector
Market Participants in the Biomarkers Space
CHAPTER 4 BIOMARKERS MARKET - LICENSING, ACQUISITIONS, COLLABORATIONS DEAL ANALYSIS=
Licensing Deals in the Biomarkers Market, 2008-2018
Licensing Deal Definition and General Structure
Valuation and Payment Structure
Analysis of Licensing Deals in the Biomarkers Market, 2008-2018
Acquisition Deals in the Biomarkers Market, 2008-2018
Acquisition Deal Definition and General Structure
Analysis of Acquisition Deals in the Biomarkers Market, 2008-2018
Partnerships/Collaboration Deals in the Biomarkers Market, 2008-2018
Collaboration Deal Definition and General Structure
Analysis of Partnership/collaboration Deals in the Biomarkers Market, 2008-2018
Analysis of Different Aspects of Licensing, Acquisition and Collaboration Deals in the Biomarkers Market
Analysis of Licensing Deals Structure in the Biomarkers Market, 2008-2018
Analysis of Acquisition Deals Structure in the Biomarkers Market, 2008-2018
Analysis of Collaboration Deals Structure in the Biomarkers Market, 2008-2018
Biomarker Market Participants Active in Licensing, Acquisitions and Partnership/Collaboration Deals, 2008-2018
Qiagen
bioMerieux
MDxHealth
Myriad Genetics
CHAPTER 5 IMPACT OF OTHER MARKETS AND CLINICAL TRIALS ON LICENSING, ACQUISITION AND COLLABORATIONS IN THE BIOMARKERS MARKET=
Cancer Diagnostics as Market Potential for Exosome-Based Diagnostics Product Development
Prostate Cancer as Potential for Biomarker Development
Breast Cancer as Potential for Biomarker Development
Bladder Cancer as Potential for Biomarker Development
Ovarian Cancer as Potential for Biomarker Development
Lung Cancer as Potential for Biomarker Development
CNS Disorders and Neurodegeneration Diseases as Market Potential for Biomarker Development
Cardiovascular Diseases as Market Potential for Biomarker Development
Organ Transplantation as Market Potential for Biomarker Development in Immune Disorders
Clinical Trials as Indicator for Biomarker Market Development
CHAPTER 6 PATENT REVIEW/NEW DEVELOPMENTS=
CHAPTER 7 MARKET SUMMARY=
CHAPTER 8 COMPANY PROFILES=
BIOMERIEUX S.A.=
INTEGRAGEN SA=
MDX HEALTH=
MYRIAD GENETICS=
PROTAGEN AG=
QIAGEN
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources and Methodology
Intended Audience
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS=
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND=
Biomarker Definition and Classification
Biomarker Applications
Biomarker Identification and Detection Technologies
Steps in Biomarker Development
Biomarker Market Analysis and Evaluation
Global Biomarker Market Value and its Segmentation
Oncology-Related Biomarkers Sector
Cardiovascular Diseases Biomarker Sector
Neurological Disorders and Other Diseases Biomarkers Sector
Market Participants in the Biomarkers Space
CHAPTER 4 BIOMARKERS MARKET - LICENSING, ACQUISITIONS, COLLABORATIONS DEAL ANALYSIS=
Licensing Deals in the Biomarkers Market, 2008-2018
Licensing Deal Definition and General Structure
Valuation and Payment Structure
Analysis of Licensing Deals in the Biomarkers Market, 2008-2018
Acquisition Deals in the Biomarkers Market, 2008-2018
Acquisition Deal Definition and General Structure
Analysis of Acquisition Deals in the Biomarkers Market, 2008-2018
Partnerships/Collaboration Deals in the Biomarkers Market, 2008-2018
Collaboration Deal Definition and General Structure
Analysis of Partnership/collaboration Deals in the Biomarkers Market, 2008-2018
Analysis of Different Aspects of Licensing, Acquisition and Collaboration Deals in the Biomarkers Market
Analysis of Licensing Deals Structure in the Biomarkers Market, 2008-2018
Analysis of Acquisition Deals Structure in the Biomarkers Market, 2008-2018
Analysis of Collaboration Deals Structure in the Biomarkers Market, 2008-2018
Biomarker Market Participants Active in Licensing, Acquisitions and Partnership/Collaboration Deals, 2008-2018
Qiagen
bioMerieux
MDxHealth
Myriad Genetics
CHAPTER 5 IMPACT OF OTHER MARKETS AND CLINICAL TRIALS ON LICENSING, ACQUISITION AND COLLABORATIONS IN THE BIOMARKERS MARKET=
Cancer Diagnostics as Market Potential for Exosome-Based Diagnostics Product Development
Prostate Cancer as Potential for Biomarker Development
Breast Cancer as Potential for Biomarker Development
Bladder Cancer as Potential for Biomarker Development
Ovarian Cancer as Potential for Biomarker Development
Lung Cancer as Potential for Biomarker Development
CNS Disorders and Neurodegeneration Diseases as Market Potential for Biomarker Development
Cardiovascular Diseases as Market Potential for Biomarker Development
Organ Transplantation as Market Potential for Biomarker Development in Immune Disorders
Clinical Trials as Indicator for Biomarker Market Development
CHAPTER 6 PATENT REVIEW/NEW DEVELOPMENTS=
CHAPTER 7 MARKET SUMMARY=
CHAPTER 8 COMPANY PROFILES=
BIOMERIEUX S.A.=
INTEGRAGEN SA=
MDX HEALTH=
MYRIAD GENETICS=
PROTAGEN AG=
QIAGEN
LIST OF TABLES
Summary Table: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018
Table 1: Biomarker Classification
Table 2: Applications of Biomarkers
Table 3: Common Techniques Used for Biomarker Identification
Table 4: Global Biomarkers Market, Through 2023
Table 5: Global Biomarker Market Share, by Application, 2018
Table 6: Examples of Cancer Biomarkers for Therapy Selection and Monitoring
Table 7: Examples of Current Cancer-Associated Antigens/Biomarkers Used in Cancer Diagnosis
Table 8: Liquid Biopsy Market, 2017 and 2018
Table 9: Global Cancer Biomarkers Market, Through 2023
Table 10: Examples of Cardiovascular Biomarkers Used for Clinical Diagnosis
Table 11: Global Cardiovascular Biomarkers Market, Through 2023
Table 12: Examples of Neurological Biomarkers for Clinical Diagnosis
Table 13: Global Biomarkers Market, by Application Sector, Through 2023
Table 14: Examples of Biomarkers Market Participants
Table 15: Overview of Common Payment Forms in Licensing Deal
Table 16: Number of Biomarker Licensing Deals in Different Biotech Sectors, 2008-2018
Table 17: Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year, 2008-2018
Table 18: Example of Licensing Deals, 2008-2018
Table 19: Number of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Table 20: Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Table 21: Purpose of Biomarker Licensing Deals, 2008-2018
Table 22: Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Table 23: Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018
Table 24: Total Number of Biomarker Acquisition Deals in Different Biotech Sectors, 2008-2018
Table 25: Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year, 2008-2018
Table 26: Examples of Acquisition Deals, 2008-2018
Table 27: Number of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018
Table 28: Share of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018
Table 29: Purpose of Biomarkers Acquisition Deals, 2008-2018
Table 30: Share of Biomarker Acquisition Deals in North America Vs. Europe, 2008-2018
Table 31: Total Number of Biomarker Collaboration Deals in Different Biotech Sectors, 2008-2018
Table 32: Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year, 2008-2018
Table 33: Examples of Partnership/Collaboration Deals in the Biomarkers Market, 2008-2018
Table 34: Number of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018
Table 35: Share of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018
Table 36: Purpose of Biomarkers Collaboration Deals, 2008-2018
Table 37: Share of Collaboration Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Table 38: Share of Biomarker Collaborations/Partnerships in North America vs. Europe, 2008-2018
Table 39: Examples of Upfront Payments in Licensing Deals, 2008-2018
Table 40: Examples of Milestone and Royalty Payments in Licensing Deals, 2008-2018
Table 41: Examples of Termination Condition in Licensing Biomarkers Deals, 2008-2018
Table 42: Global Biomarkers Licensing Deals Market, 2014-2018
Table 43: Examples of Acquisition Deals Values in the Biomarkers Market, 2008-2018
Table 44: Global Value of Biomarkers Acquisition Deals, 2014-2018
Table 45: Examples of Upfront Payments and Total Value in Collaboration Deals, 2008-2018
Table 46: Share of Upfront Payments from Total Value in Collaboration Deals, 2008-2018
Table 47: Examples of Milestones and Royalty Payments in Collaboration Deals, 2008-2018
Table 48: Examples of Termination Conditions in Collaboration Biomarkers Deals, 2008-2018
Table 49: Global Value of Biomarkers Partnership Deals, 2014-2018
Table 50: Examples of Biomarker Market Participants in Licensing, Collaboration and Acquisition Deals, 2008-2018
Table 51: Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity, 2008-2018
Table 52: Financial Data for Qiagen, 2015-2017
Table 53: Financial Data for bioMerieux, 2015-2017
Table 54: Financial Data for MDxHealth, 2015-2017
Table 55: Financial Data for Myriad Genetics, 2015-2017
Table 56: Statistics for Prostate Cancer, 2017
Table 57: Global Prostate Cancer Diagnostics Market and Related Cost, 2018-2023
Table 58: Statistics for Breast Cancer, 2017
Table 59: Global Market for Breast Cancer Diagnostics, Through 2019
Table 60: Statistics for Bladder Cancer, 2017
Table 61: Global Market for Bladder Cancer Diagnostics, 2017
Table 62: Statistics for Ovarian Cancer, 2017
Table 63: Global Ovarian Cancer Diagnostics Market, 2017
Table 64: Statistics for Lung Cancer, 2017
Table 65: Global Lung Cancer Diagnostics Market, 2017
Table 66: U.S. Statistics Data for Alzheimer’s, 2017
Table 67: Global Market for Alzheimer’s Disease Therapeutics and Diagnostics, Through 2020
Table 68: U.S. Statistics Data for Cardiovascular Diseases, 2017
Table 69: Global Cardiovascular Diagnostics Market, 2017
Table 70: Global Organ and Tissue Transplantation Products and Devices Market, Through 2020
Table 71: Number of Clinical Trials on Biomarkers Per Year, 2008-2017
Table 72: Search Analysis for Clinical Trials Using Specific Keywords
Table 73: Distribution of Clinical Trials on Biomarkers Based on Different Stages of Clinical Trials
Table 74: Analysis of Biomarker Clinical Trials, Based on Sponsor
Table 75: Examples of Clinical Trials Related to Biomarker R&D
Table 76: Number of Clinical Trials Sponsored by Some Biomarker Market Participants
Table 77: Number of Patents and Patent Applications Filed on Biomarkers, by Year, 2008-2017
Table 78: Examples of Patents and Patent Applications Filed on Biomarkers, 2008-2017
Table 79: Search Analysis for Patents and Patent Applications Using Keyword Combinations
Table 80: Number of Patents and Patent Applications, by Company
Table 81: Examples of Patents and Patent Applications Filed on Biomarkers, by Company
Table 82: Global Value of Biomarkers Licensing, Acquisition and Partnership Deals, by Type, 2014-2018
Table 83: Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Table 84: Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity
Summary Table: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018
Table 1: Biomarker Classification
Table 2: Applications of Biomarkers
Table 3: Common Techniques Used for Biomarker Identification
Table 4: Global Biomarkers Market, Through 2023
Table 5: Global Biomarker Market Share, by Application, 2018
Table 6: Examples of Cancer Biomarkers for Therapy Selection and Monitoring
Table 7: Examples of Current Cancer-Associated Antigens/Biomarkers Used in Cancer Diagnosis
Table 8: Liquid Biopsy Market, 2017 and 2018
Table 9: Global Cancer Biomarkers Market, Through 2023
Table 10: Examples of Cardiovascular Biomarkers Used for Clinical Diagnosis
Table 11: Global Cardiovascular Biomarkers Market, Through 2023
Table 12: Examples of Neurological Biomarkers for Clinical Diagnosis
Table 13: Global Biomarkers Market, by Application Sector, Through 2023
Table 14: Examples of Biomarkers Market Participants
Table 15: Overview of Common Payment Forms in Licensing Deal
Table 16: Number of Biomarker Licensing Deals in Different Biotech Sectors, 2008-2018
Table 17: Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year, 2008-2018
Table 18: Example of Licensing Deals, 2008-2018
Table 19: Number of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Table 20: Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Table 21: Purpose of Biomarker Licensing Deals, 2008-2018
Table 22: Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Table 23: Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018
Table 24: Total Number of Biomarker Acquisition Deals in Different Biotech Sectors, 2008-2018
Table 25: Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year, 2008-2018
Table 26: Examples of Acquisition Deals, 2008-2018
Table 27: Number of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018
Table 28: Share of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018
Table 29: Purpose of Biomarkers Acquisition Deals, 2008-2018
Table 30: Share of Biomarker Acquisition Deals in North America Vs. Europe, 2008-2018
Table 31: Total Number of Biomarker Collaboration Deals in Different Biotech Sectors, 2008-2018
Table 32: Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year, 2008-2018
Table 33: Examples of Partnership/Collaboration Deals in the Biomarkers Market, 2008-2018
Table 34: Number of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018
Table 35: Share of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018
Table 36: Purpose of Biomarkers Collaboration Deals, 2008-2018
Table 37: Share of Collaboration Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Table 38: Share of Biomarker Collaborations/Partnerships in North America vs. Europe, 2008-2018
Table 39: Examples of Upfront Payments in Licensing Deals, 2008-2018
Table 40: Examples of Milestone and Royalty Payments in Licensing Deals, 2008-2018
Table 41: Examples of Termination Condition in Licensing Biomarkers Deals, 2008-2018
Table 42: Global Biomarkers Licensing Deals Market, 2014-2018
Table 43: Examples of Acquisition Deals Values in the Biomarkers Market, 2008-2018
Table 44: Global Value of Biomarkers Acquisition Deals, 2014-2018
Table 45: Examples of Upfront Payments and Total Value in Collaboration Deals, 2008-2018
Table 46: Share of Upfront Payments from Total Value in Collaboration Deals, 2008-2018
Table 47: Examples of Milestones and Royalty Payments in Collaboration Deals, 2008-2018
Table 48: Examples of Termination Conditions in Collaboration Biomarkers Deals, 2008-2018
Table 49: Global Value of Biomarkers Partnership Deals, 2014-2018
Table 50: Examples of Biomarker Market Participants in Licensing, Collaboration and Acquisition Deals, 2008-2018
Table 51: Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity, 2008-2018
Table 52: Financial Data for Qiagen, 2015-2017
Table 53: Financial Data for bioMerieux, 2015-2017
Table 54: Financial Data for MDxHealth, 2015-2017
Table 55: Financial Data for Myriad Genetics, 2015-2017
Table 56: Statistics for Prostate Cancer, 2017
Table 57: Global Prostate Cancer Diagnostics Market and Related Cost, 2018-2023
Table 58: Statistics for Breast Cancer, 2017
Table 59: Global Market for Breast Cancer Diagnostics, Through 2019
Table 60: Statistics for Bladder Cancer, 2017
Table 61: Global Market for Bladder Cancer Diagnostics, 2017
Table 62: Statistics for Ovarian Cancer, 2017
Table 63: Global Ovarian Cancer Diagnostics Market, 2017
Table 64: Statistics for Lung Cancer, 2017
Table 65: Global Lung Cancer Diagnostics Market, 2017
Table 66: U.S. Statistics Data for Alzheimer’s, 2017
Table 67: Global Market for Alzheimer’s Disease Therapeutics and Diagnostics, Through 2020
Table 68: U.S. Statistics Data for Cardiovascular Diseases, 2017
Table 69: Global Cardiovascular Diagnostics Market, 2017
Table 70: Global Organ and Tissue Transplantation Products and Devices Market, Through 2020
Table 71: Number of Clinical Trials on Biomarkers Per Year, 2008-2017
Table 72: Search Analysis for Clinical Trials Using Specific Keywords
Table 73: Distribution of Clinical Trials on Biomarkers Based on Different Stages of Clinical Trials
Table 74: Analysis of Biomarker Clinical Trials, Based on Sponsor
Table 75: Examples of Clinical Trials Related to Biomarker R&D
Table 76: Number of Clinical Trials Sponsored by Some Biomarker Market Participants
Table 77: Number of Patents and Patent Applications Filed on Biomarkers, by Year, 2008-2017
Table 78: Examples of Patents and Patent Applications Filed on Biomarkers, 2008-2017
Table 79: Search Analysis for Patents and Patent Applications Using Keyword Combinations
Table 80: Number of Patents and Patent Applications, by Company
Table 81: Examples of Patents and Patent Applications Filed on Biomarkers, by Company
Table 82: Global Value of Biomarkers Licensing, Acquisition and Partnership Deals, by Type, 2014-2018
Table 83: Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Table 84: Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity
LIST OF FIGURES
Summary Figure: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018
Figure 1: Schematic Presentation of Biomarker Development Process During Drug Development
Figure 2: Global Biomarkers Market, 2016-2023
Figure 3: Number of Biomarker Licensing Deals in Different Biotech Sectors, 2008-2018
Figure 4: Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year, 2008-2018
Figure 5: Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Figure 6: Purpose of Biomarker Licensing Deals, 2008-2018
Figure 7: Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Figure 8: Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018
Figure 9: Total Number of Biomarker Acquisition Deals in Different Biotech Sectors, 2008-2018
Figure 10: Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year, 2008-2018
Figure 11: Share of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018
Figure 12: Purpose of Biomarkers Acquisition Deals, 2008-2018
Figure 13: Share of Biomarker Acquisition Deals in North America Vs. Europe, 2008-2018
Figure 14: Total Number of Biomarker Collaboration Deals in Different Biotech Sectors, 2008-2018
Figure 15: Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year, 2008-2018
Figure 16: Share of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018
Figure 17: Purpose of Biomarkers Collaboration Deals, 2008-2018
Figure 18: Share of Collaboration Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Figure 19: Share of Biomarker Collaboration/Partnerships in North America vs. Europe, 2008-2018
Figure 20: Global Biomarkers Licensing Deals Market, 2014-2018
Figure 21: Global Biomarkers Acquisition Deals Market, 2014-2018
Figure 22: Global Biomarkers Partnership Deals Market, 2014-2018
Figure 23: Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity, 2008-2018
Figure 24: Number of Clinical Trials on Biomarkers Per Year, 2008-2017
Figure 25: Search Analysis for Clinical Trials Using Specific Keywords
Figure 26: Distribution of Clinical Trials on Biomarkers Based on Different Stages of Clinical Trials
Figure 27: Number of Patents and Patent Applications Filed on Biomarkers, by Year, 2008-2017
Figure 28: Search Analysis for Patents and Patent Applications Using Keyword Combinations
Figure 29: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018
Summary Figure: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018
Figure 1: Schematic Presentation of Biomarker Development Process During Drug Development
Figure 2: Global Biomarkers Market, 2016-2023
Figure 3: Number of Biomarker Licensing Deals in Different Biotech Sectors, 2008-2018
Figure 4: Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year, 2008-2018
Figure 5: Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018
Figure 6: Purpose of Biomarker Licensing Deals, 2008-2018
Figure 7: Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Figure 8: Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018
Figure 9: Total Number of Biomarker Acquisition Deals in Different Biotech Sectors, 2008-2018
Figure 10: Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year, 2008-2018
Figure 11: Share of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018
Figure 12: Purpose of Biomarkers Acquisition Deals, 2008-2018
Figure 13: Share of Biomarker Acquisition Deals in North America Vs. Europe, 2008-2018
Figure 14: Total Number of Biomarker Collaboration Deals in Different Biotech Sectors, 2008-2018
Figure 15: Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year, 2008-2018
Figure 16: Share of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018
Figure 17: Purpose of Biomarkers Collaboration Deals, 2008-2018
Figure 18: Share of Collaboration Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018
Figure 19: Share of Biomarker Collaboration/Partnerships in North America vs. Europe, 2008-2018
Figure 20: Global Biomarkers Licensing Deals Market, 2014-2018
Figure 21: Global Biomarkers Acquisition Deals Market, 2014-2018
Figure 22: Global Biomarkers Partnership Deals Market, 2014-2018
Figure 23: Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity, 2008-2018
Figure 24: Number of Clinical Trials on Biomarkers Per Year, 2008-2017
Figure 25: Search Analysis for Clinical Trials Using Specific Keywords
Figure 26: Distribution of Clinical Trials on Biomarkers Based on Different Stages of Clinical Trials
Figure 27: Number of Patents and Patent Applications Filed on Biomarkers, by Year, 2008-2017
Figure 28: Search Analysis for Patents and Patent Applications Using Keyword Combinations
Figure 29: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018
